NASDAQ:ARRY - Array Biopharma Stock Price, Price Target & More

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

Array Biopharma Inc (NASDAQ:ARRY) announced its quarterly earnings data on Wednesday, May, 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.22) by $0.11. The biopharmaceutical company had revenue of $66.37 million for the quarter, compared to analyst estimates of $28.81 million. Array Biopharma had a negative net margin of 72.33% and a negative return on equity of 96.65%. The company's revenue was up 99.4% on a year-over-year basis. During the same period last year, the business earned ($0.21) EPS. View Array Biopharma's Earnings History.

Array Biopharma is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Array Biopharma.

8 analysts have issued 12 month target prices for Array Biopharma's stock. Their forecasts range from $13.00 to $24.00. On average, they expect Array Biopharma's share price to reach $18.3750 in the next twelve months. View Analyst Ratings for Array Biopharma.

Array Biopharma saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 15,870,987 shares, an increase of 21.4% from the April 30th total of 13,075,730 shares. Based on an average trading volume of 2,971,569 shares, the short-interest ratio is presently 5.3 days. Currently, 7.7% of the company's stock are sold short.

Some companies that are related to Array Biopharma include Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Alnylam Pharmaceuticals (ALNY), Perrigo (PRGO), Nektar Therapeutics (NKTR), BeiGene (BGNE), Genmab A/S (GNMSF), Valeant Pharmaceuticals Intl (VRX), Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO) and Catalent (CTLT).

Media stories about ARRY stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies positive and negative media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Array Biopharma earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.38 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Array Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.68%), Franklin Resources Inc. (3.96%), BVF Inc. IL (2.44%), Farallon Capital Management LLC (1.47%), Pinnacle Associates Ltd. (1.25%) and Northern Trust Corp (1.17%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Redmile Group, Llc, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.

ARRY stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., BVF Inc. IL, venBio Select Advisor LLC, Franklin Resources Inc., Eversept Partners LLC, Pinnacle Associates Ltd., Trexquant Investment LP and Russell Investments Group Ltd.. Company insiders that have sold Array Biopharma company stock in the last year include Andrew R Robbins, Charles M Baum, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Ron Squarer and Victor Sandor. View Insider Buying and Selling for Array Biopharma.

ARRY stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, American Century Companies Inc., Columbus Circle Investors, Neuberger Berman Group LLC, BlackRock Inc., PointState Capital LP, A.R.T. Advisors LLC and UBS Group AG. View Insider Buying and Selling for Array Biopharma.

Shares of ARRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ARRY stock can currently be purchased for approximately $20.04.

Array Biopharma has a market capitalization of $3.69 billion and generates $150.85 million in revenue each year. The biopharmaceutical company earns $-116,810,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Array Biopharma employs 209 workers across the globe.

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]